Michael H. Bill joined the MJ team in 1992 as a consultant in the Risk Management + Commercial Insurance department, following his tenure at a nationwide insurance carrier, where he acquired extensive industry knowledge. In 2001, he assumed the role of president, and in 2006, he was appointed as chief executive officer, a role he continues to occupy today.
As MJ’s visionary CEO, Michael provides effective leadership and decision-making, fostering a positive company culture and ensuring the overall success and sustainability of the firm. He leads and is an active member of MJ’s Executive Leadership Team, a team responsible for developing the strategic direction of the organization in alignment with our purpose.
Related Blogs
Health Care Industry Trends to Watch in 2026
Health care organizations enter 2026 facing numerous operational, financial and liability pressures, including labor shortages, inflation, supply chain volatility and the impact of U.S. ...
Read More
2025 Ended with Softest Market Conditions Since 2017 for all Account Sizes & Majority of Lines of Business, The Council’s P/C Market Survey Shows
The market appeared to move further into the soft part of the insurance market cycle in Q4 2025. Premiums across all account sizes rose ...
Read More
Miles for Miles Helps People With Intellectual and Developmental Disabilities Thrive
Miles Peck loves school as much for the chance to spend time with his friends as for the classroom experience. He is bracing his ...
Read More
EBSA Updates National Employee Benefit Plan Enforcement Projects for 2026
The Employee Benefits Security Administration (EBSA) announced updates to its national enforcement projects for fiscal year 2026. According to EBSA, these projects highlight areas ...
Read More
The Hard Market Is Shifting—Here’s What That Means for YOU
For years, organizations have been told the same thing at renewal: higher costs, fewer options, and little room to negotiate. Now, that message is ...
Read More
Employer Response to Pharma Shifts
Volatility in the pharmaceutical industry, including the expanding specialty drug pipeline, increased utilization of GLP-1 medications, and persistent supply chain disruptions, are contributing to rising costs ...
Read More